Vincristine

CHEMBL90555 Phase 4 Одобрено Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

825.0 g/mol

LogP

2.8

Phase

4

This plant-derived chemotherapy medication disrupts the formation of the mitotic spindle that cancer cells need to divide, and is a mainstay of treatment for leukemia, lymphoma, and certain pediatric solid tumors. It is given intravenously and is notable for causing peripheral neuropathy — numbness, tingling, and weakness in the hands and feet — as its main dose-limiting side effect. Accidental administration into the spinal canal (intrathecal) is invariably fatal, so strict safety protocols are in place.

Молекулярная масса

825,0000 g/mol

LogP

2,80

TPSA

171,00 Å²

Правило пяти Липинского

Не соответствует

Терапевтические области

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Melanoma Oncology Gastroesophageal Reflux Disease Inflammatory Bowel Disease Non-Alcoholic Fatty Liver Disease Lymphoma Breast Cancer HIV/AIDS Prostate Cancer Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Структура

SVG PNG

Cite this structure

Embed this structure

SMILES

CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1

InChI

InChI=1S/C46H56N4O10/c1-7-42(55)22-28-23-45(40(53)58-5,36-30(14-18-48(24-28)25-42)29-12-9-10-13-33(29)47-36)32-20-31-34(21-35(32)57-4)50(26-51)38-44(31)16-19-49-17-11-15-43(8-2,37(44)49)39(60-27(3)52)46(38,56)41(54)59-6/h9-13,15,20-21,26,28,37-39,47,55-56H,7-8,14,16-19,22-25H2,1-6H3/t28-,37+,38-,39-,42+,43-,44-,45+,46+/m1/s1

Molecular Formula

C46H56N4O10

HBD / HBA

3 / 12

Вращаемые Связи

10

Тяжёлые Атомы

60

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Часто задаваемые вопросы

This plant-derived chemotherapy medication disrupts the formation of the mitotic spindle that cancer cells need to divide, and is a mainstay of treatment for leukemia, lymphoma, and certain pediatric solid tumors. It is given intravenously and is notable for causing peripheral neuropathy — numbness, tingling, and weakness in the hands and feet — as its main dose-limiting side effect. Accidental administration into the spinal canal (intrathecal) is invariably fatal, so strict safety protocols are in place.

Yes, Vincristine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL90555. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5978. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Ищете информацию, доступную для пациентов?

Vincristine на PillFYI

Структура

Краткие Данные

Формула: C46H56N4O10

Внешние ссылки

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Медицинский отказ от ответственности

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.